Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
203.98
+2.76 (1.37%)
At close: Apr 28, 2026, 4:00 PM EDT
181.90
-22.08 (-10.82%)
After-hours: Apr 28, 2026, 7:06 PM EDT
Jazz Pharmaceuticals Employees
Jazz Pharmaceuticals had 2,890 employees as of December 31, 2025. The number of employees increased by 90 or 3.21% compared to the previous year.
Employees
2,890
Change (1Y)
90
Growth (1Y)
3.21%
Revenue / Employee
$1,476,673
Profits / Employee
-$123,235
Market Cap
12.56B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,890 | 90 | 3.21% |
| Dec 31, 2024 | 2,800 | 0 | - |
| Dec 31, 2023 | 2,800 | 0 | - |
| Dec 31, 2022 | 2,800 | -400 | -12.50% |
| Dec 31, 2021 | 3,200 | 1,260 | 64.95% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 2,973 |
| Ionis Pharmaceuticals | 1,402 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Axsome Therapeutics | 925 |
| Madrigal Pharmaceuticals | 915 |
| BridgeBio Pharma | 839 |
JAZZ News
- 1 day ago - Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA - PRNewsWire
- 7 days ago - Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 - PRNewsWire
- 7 days ago - Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin) - PRNewsWire
- 13 days ago - Jazz Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 19 days ago - Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting - PRNewsWire
- 27 days ago - Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference - PRNewsWire
- 5 weeks ago - American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education - PRNewsWire
- 5 weeks ago - Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 - PRNewsWire